Skip to content

Ketamine: all studies

Page 209 of 449: studies 2,081 to 2,090 of 4,483, newest first. Back to the ketamine overview

Research

A qualitative and quantitative account of patient's experiences of ketamine and its antidepressant properties.

Journal of Psychopharmacology August 1, 2021 Rachael Sumner, Emme Chacko, Rebecca McMillan et al. 68 citations

Ketamine is central to one of the most rapidly growing areas of neuroscientific research into novel treatments for depression. Limited research has indicated that the psychedelic properties of ketamine may play a role in its antidepressant effects. The aim of the current study was to explore the psychedelic experiences and sustained impact of ketamine in major depressive disorder. In the...

Treating Depression Using Ketamine

Sumerianz journal of social science July 24, 2021 C. Griffith

Unipolar major depressive disorder affects a significant number of individuals across the globe placing at the top of the list as the leading cause of disability, related to damaging ramifications on the well-being affected persons and the societies. The current standard antidepressants targeting monoamine systems take long in starting a response. Therefore, there is a need in depression...

Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study

Medicine July 23, 2021 A. Włodarczyk, Wiesław Jerzy Cubała, Maria Gałuszko‐węgielnik et al. 23 citations

Abstract There is evidence for ketamine use in treatment-resistant depression (TRD). Several safety and tolerability concerns arise regarding adverse drug reactions and specific subpopulations. This paper aims to investigate the relationship between dissociative and psychometric measures in course of intravenous ketamine treatment in TRD inpatients with major depressive disorder and bipolar...

Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study

CNS Drugs July 20, 2021 Vera Miriam Ludwig, Cathrin Sauer, Allan H. Young et al. 23 citations

(Es)ketamine and monoamine oxidase inhibitors (MAOIs), e.g., tranylcypromine, are therapeutic options for treatment-resistant major depression. Simultaneous administration is currently not recommended because of concern about hypertensive crises. Our objective was to evaluate whether changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) during esketamine...

DOI: 10.1007/s40263-021-00837-6 (opens in new tab) Full text (opens in new tab) Tranylcypromine Psychopharmacology Retrospective cohort study Depression economics +4

Ketamine Treatment for Depression in Patients With a History of Psychosis or Current Psychotic Symptoms: A Systematic Review.

The Journal of Clinical Psychiatry July 13, 2021 Jolien K E Veraart, Sanne Y Smith-Apeldoorn, Jan Spijker et al. 31 citations

Objective: Ketamine shows rapid and robust antidepressant effects in clinical studies. Psychotic features are an exclusion criterion in most ketamine treatment studies based on the assumption that psychosis will increase with ketamine administration. As patients with treatment-resistant depression (TRD) often have psychotic features, and treatment-resistant depressive symptoms are also common...

Modulating amygdala activation to traumatic memories with a single ketamine infusion

medRxiv Preprint Server July 7, 2021 Or Duek, Yutong Li, Ben Kelmendi et al. 8 citations preprint

NMDA receptor antagonists have a vital role in extinction, learning, and reconsolidation processes. During the reconsolidation window, memories are activated into a labile state and can be stored in an altered form. This concept might have significant clinical implications in treating PTSD. Using amygdala activity as a major biomarker of fear response, we tested the potential of a single...

DOI: 10.1101/2021.07.07.21260166 (opens in new tab) Full text (opens in new tab) Trauma memory alteration Ketamine intervention Memory reconsolidation

Combined Low Dose of Ketamine and Social Isolation: A Possible Model of Induced Chronic Schizophrenia-Like Symptoms in Male Albino Rats

Brain Science July 1, 2021 Suzanne Estaphan, A. Curpan, D. Khalifa et al.

While animal models for schizophrenia, ranging from pharmacological models to lesions and genetic models, are available, they usually mimic only the positive symptoms of this disorder. Identifying a feasible model of chronic schizophrenia would be valuable for studying the possible underlying mechanism and to investigate emerging treatments. Our hypothesis starts from the observation that...

Opioid Properties of Nitrous Oxide and Ketamine Contribute to Their Antidepressant Actions

The International Journal of Neuropsychopharmacology July 1, 2021 M. Gillman

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. © The Author(s) 2021. Published by Oxford University Press on behalf of CINP. Letter to Editor Opioid Properties of...

Therapeutic potential of ketamine for alcohol use disorder.

Neuroscience & Biobehavioral Reviews July 1, 2021 Stephen D Worrell, Thomas J Gould 47 citations

Excessive alcohol consumption is involved in 1/10 of deaths of U.S. working-age adults and costs the country around $250,000,000 yearly. While Alcohol Use Disorder (AUD) pathology is complex and involves multiple neurotransmitter systems, changes in synaptic plasticity, hippocampal neurogenesis, and neural connectivity have been implicated in the behavioral characteristics of AUD. Depressed...

Ketamine for Treatment-Resistant Depression

Mustansiriya Medical Journal July 1, 2021 Raad Saady Madhloom

Major depressive disorder (MDD) is of influence on about 350 million individuals worldwide, which is causing disability consecution and damaging consequences to the affected community and individuals. Treatments as antidepressant are affecting the system of monoamine where symptoms of depressive were relived in about 50% of cases. Such ratio turns into obviously low in depressed persons who...